Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome

Familial Cancer

Volumn 9, Issue 2, 2010, Pages 173-179

  Reuschenbach, Miriam ^a,b   Kloor, Matthias ^a,b   Morak, Monika ^c   Wentzensen, Nicolas ^a,b,d   Germann, Anja ^a,b   Garbe, Yvette ^a,b   Tariverdian, Mirjam ^e   Findeisen, Peter ^f   Neumaier, Michael ^f   Holinski Feder, Elke ^c   Doeberitz, Magnus Von Knebel ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antibodies; Frameshift peptides; Immune responses; Lynch syndrome; Microsatellite instability

Indexed keywords

ADULT; AGED; AMINO ACID SEQUENCE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL CANCER; FEMALE; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL;

ANTIBODIES; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FRAMESHIFT MUTATION; HUMANS; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MUTS HOMOLOG 2 PROTEIN; PEPTIDES;

EID: 77955049941     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-009-9307-z     Document Type: Article

References (25)

1. Ionov Y, Peinado MA, Malkhosyan S et al (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558-561
2. Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260:816-819
3. Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348:919-932
4. Quehenberger F, Vasen HF, van Houwelingen HC (2005) Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 42:491-496
5. Hampel H, Frankel WL, Martin E et al (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783-5788
6. Watson P, Lin KM, Rodriguez-Bigas MA et al (1998) Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer 83:259-266 (Pubitemid 28317805)
7. Dolcetti R, Viel A, Doglioni C et al (1999) High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 154:1805-1813
8. Buckowitz A, Knaebel HP, Benner A et al (2005) Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer 92:1746-1753
9. Banerjea A, Bustin SA, Dorudi S (2005) The immunogenicity of colorectal cancers with high-degree microsatellite instability. World J Surg Oncol 3:26
10. Lynch HT, Drescher KM, de la Chapelle A (2008) Immunology and the Lynch syndrome. Gastroenterology 134:1246-1249
11. Saeterdal I, Bjorheim J, Lislerud K et al (2001) Frameshiftmutation- derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 98:13255-13260
12. Woerner SM, Benner A, Sutter C et al (2003) Pathogenesis of DNA repair-deficient cancers: a statistical meta-analysis of putative Real Common Target genes. Oncogene 22:2226-2235
13. Woerner SM, Kloor M, von Knebel Doeberitz M et al (2006) Microsatellite instability in the development of DNA mismatch repair deficient tumors. Cancer Biomark 2:69-86
14. Schwitalle Y, Kloor M, Eiermann S et al (2008) Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134:988-997
15. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N (2009) A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58:1535-1544
16. Ishikawa T, Fujita T, Suzuki Y et al (2003) Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res 63:5564-5572
17. Steinitz M, Baraz L (2000) A rapid method for estimating the binding of ligands to ELISA microwells. J Immunol Methods 238:143-150
18. Reuschenbach M, Waterboer T, Wallin KL et al (2008) Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int J Cancer 123:2626-2631
19. Korangy F, Ormandy LA, Bleck JS et al (2004) Spontaneous tumor-specific humoral and cellular immune responses to NYESO-1 in hepatocellular carcinoma. Clin Cancer Res 10:4332-4341
20. Jäger E, Stockert E, Zidianakis Z et al (1999) Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 84:506-510
21. Shimada H, Takeda A, Arima M et al (2000) Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677-1683
22. Lu H, Goodell V, Disis ML (2008) Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 7:1388-1394
23. Zhang JY, Casiano CA, Peng XX et al (2003) Enhancement of antibody detection in cancer using panel of recombinant tumorassociated antigens. Cancer Epidemiol Biomarkers Prev 12:136-143
24. Montgomery RB, Makary E, Schiffman K et al (2005) Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 65:650-656
25. Speetjens FM, Kuppen PJ, Morreau H et al (2008) Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 135:711-712